AN-1792 Elan

Current Opinion in Investigational Drugs

Volumn 2, Issue 5, 2001, Pages 663-667

  Thatte, U ^a  

^a KEM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETABLOC; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOMODULATING AGENT; PLACEBO; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIBODY TITER; CLINICAL TRIAL; COGNITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; NONHUMAN; REVIEW; SENILE PLAQUE; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TASK PERFORMANCE; TREATMENT OUTCOME; WORKING MEMORY;

ADJUVANTS, IMMUNOLOGIC; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; CLINICAL TRIALS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; VACCINES;

EID: 0034990745     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Experimental therapy may be useful in treating and preventing Alzheimer's disease
2. Merrill Lynch: Global Pharmaceutical Biotechnology & Medical Device Bulletin
3. Elan's Betabloc enters clinical studies for treatment of Alzheimer's disease
4. Elan to commence UK multiple dose clinical study with Betabloc in Alzheimer patients
5. American Home Products and Elan forge biotech alliance to develop Alzheimer's vaccine - Partnership joins two biotechnology leaders to address important medical need
6. Advances in Alzheimer Therapy - Sixth International Stockholm/Springfield Symposium (Part III), Stockholm, Sweden
7. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP
8. Annual Report 1999 - Elan Corp
9. Scientists announce initial results of Alzheimer vaccine treatment in humans: Research confirms vaccine's mechanism of action
10. Elan Alzheimer's peptide vaccine to enter phase II/III by end of 2001
11. Merrill Lynch: Global Healthcare Bulletin
12. Drug development pipeline - AN-1792
13. Merrill Lynch: Pharmaceuticals: Speciality pharmaceuticals model and pipeline book: 2nd (June) Quarter 2000 issue
14. Antibodies against Aβ reduce amyloid burden in vivo
15. Anti-amyloid-β antibodies promote clearance of amyloid-β deposits imaged in vivo in PDAPP mice
16. Therapeutic approaches to Alzheimer's disease
17. Merrill Lynch: United Kingdom Biotechnology: Cambridge Antibody Technology
18. Promising vaccine for treatment of Alzheimer disease found
19. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
20. A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
21. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
22. A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
23. Vaccine improves memory in "Alzheimer's" mice
24. Drug development pipeline - Myobloc and AN-1792
25. Elan Corporation plc
26. Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of β-APP
27. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x- 41) and tau